<DOC>
	<DOCNO>NCT02199964</DOCNO>
	<brief_summary>This study test hypothesis topical administration FDA approve immunomodulatory agent cyclosporin A emulsion minimize irritation ocular surface disease result short term low humidity environmental stress</brief_summary>
	<brief_title>The Effects Cyclosporin A Low Humidity Environment , Ocular Surface</brief_title>
	<detailed_description>This pilot study design evaluate effect two conventional dry eye therapy , artificial tear hydrate cyclosporine A anti-inflammatory , irritation symptom ocular surface disease dry eye patient expose low humidity environment 90 minute . Patients dry eye enrol study complete validate symptom questionnaire undergo complete ocular surface tear examination characterize disease . Enrolled subject expose low humidity environment initial evaluation prior treatment expose low humidity environment second time . They randomize receive either artificial tear 0.05 % cyclosporine A emulsion drop four time day 6 week .</detailed_description>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Lubricant Eye Drops</mesh_term>
	<criteria>Signature write informed consent form Patient willingness ability return visit study Rapid tear film break time seven second less least one eye AND Both cornea fluorescein stain score great equal 3 conjunctival lissamine green stain great equal 3 least one eye Ocular Surface Disease Index Symptom Severity score twenty great Tear meniscus height less equal 230um Intact corneal sensitivity Willingness discontinue use current dry eye treatment ( except artificial tear ) four week prior enrollment , course study Compromised cognitive ability may expect interfere study compliance Uncontrolled poorly control diabetes heart pulmonary disease could , judgment investigator , jeopardize subject safety interfere interpretation result study Known hypersensitivity component artificial tear cyclosporin A eye drop Anticipated contact lens wear study History corneal transplant Active ocular infection , uveitis nonKCS related inflammation History cataract surgery within 3 month prior enrollment History pterygium removal within 6 month prior enrollment Reduced corneal sensitivity Initiation , discontinuation change dosage hormone replacement therapy ( HRT ) , fish oil , even primrose , flaxseed , black current seed oil supplement , antihistamine , cholinergic agent , betablocking agent , tricyclic SSRI antidepressant , phenothiazine , topical systemic acne rosacea medication two month prior enrollment , anticipated change dosage course study Topical ophthalmic medication within prior 4 week , anticipate use study ( except artificial tear ) Occlusion lacrimal puncta either surgically temporary collagen punctal plug within three month prior study , anticipate use study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Dry eye</keyword>
	<keyword>environmental stress</keyword>
	<keyword>artificial tear</keyword>
	<keyword>cyclosporin</keyword>
	<keyword>Restasis</keyword>
</DOC>